The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
The global Painful Diabetic Neuropathy Drug market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Painful Diabetic Neuropathy Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Painful Diabetic Neuropathy Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Highlights
The global market for Painful Diabetic Neuropathy Drug in Hospital is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global companies of Painful Diabetic Neuropathy Drug include Daiichi Sankyo Company, Limited, Eli Lilly and Company, Johnson & Johnson Services, Inc, Novartis AG, Pfizer Inc., Grunenthal GmbH, ViroMed Co., Collegium Pharmaceutical, Inc and Acorda Therapeutics, Inc, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19, Oral, which accounted for % of the global market of Painful Diabetic Neuropathy Drug in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Painful Diabetic Neuropathy Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Painful Diabetic Neuropathy Drug.
The Painful Diabetic Neuropathy Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Painful Diabetic Neuropathy Drug market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Painful Diabetic Neuropathy Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
- Daiichi Sankyo Company, Limited
- Eli Lilly and Company
- Johnson & Johnson Services, Inc
- Novartis AG
- Pfizer Inc.
- Grunenthal GmbH
- ViroMed Co.
- Collegium Pharmaceutical, Inc
- Acorda Therapeutics, Inc
- Zydus Pharmaceuticals
- Mallinckrodt, Inc
- Macleods Pharmaceuticals Ltd.
- Lupin Pharmaceuticals
Product Type Insights
Global markets are presented by Painful Diabetic Neuropathy Drug type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the Painful Diabetic Neuropathy Drug are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Painful Diabetic Neuropathy Drug segment by Type
- Oral
- Injection
- Others
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Painful Diabetic Neuropathy Drug market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Painful Diabetic Neuropathy Drug market.
Painful Diabetic Neuropathy Drug Segment by Application
- Hospital
- Clinic
- Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina, Colombia)
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Painful Diabetic Neuropathy Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
- This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Painful Diabetic Neuropathy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
- This report will help stakeholders to understand the global industry status and trends of Painful Diabetic Neuropathy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
- This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
- This report stays updated with novel technology integration, features, and the latest developments in the market
- This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Painful Diabetic Neuropathy Drug industry.
- This report helps stakeholders to gain insights into which regions to target globally
- This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Painful Diabetic Neuropathy Drug.
- This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Painful Diabetic Neuropathy Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Painful Diabetic Neuropathy Drug Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Injection
1.2.4 Others
1.3 Market by Application
1.3.1 Global Painful Diabetic Neuropathy Drug Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Painful Diabetic Neuropathy Drug Market Perspective (2017-2028)
2.2 Painful Diabetic Neuropathy Drug Growth Trends by Region
2.2.1 Painful Diabetic Neuropathy Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Painful Diabetic Neuropathy Drug Historic Market Size by Region (2017-2022)
2.2.3 Painful Diabetic Neuropathy Drug Forecasted Market Size by Region (2023-2028)
2.3 Painful Diabetic Neuropathy Drug Market Dynamics
2.3.1 Painful Diabetic Neuropathy Drug Industry Trends
2.3.2 Painful Diabetic Neuropathy Drug Market Drivers
2.3.3 Painful Diabetic Neuropathy Drug Market Challenges
2.3.4 Painful Diabetic Neuropathy Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Painful Diabetic Neuropathy Drug Players by Revenue
3.1.1 Global Top Painful Diabetic Neuropathy Drug Players by Revenue (2017-2022)
3.1.2 Global Painful Diabetic Neuropathy Drug Revenue Market Share by Players (2017-2022)
3.2 Global Painful Diabetic Neuropathy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Painful Diabetic Neuropathy Drug Revenue
3.4 Global Painful Diabetic Neuropathy Drug Market Concentration Ratio
3.4.1 Global Painful Diabetic Neuropathy Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Painful Diabetic Neuropathy Drug Revenue in 2021
3.5 Painful Diabetic Neuropathy Drug Key Players Head office and Area Served
3.6 Key Players Painful Diabetic Neuropathy Drug Product Solution and Service
3.7 Date of Enter into Painful Diabetic Neuropathy Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Painful Diabetic Neuropathy Drug Breakdown Data by Type
4.1 Global Painful Diabetic Neuropathy Drug Historic Market Size by Type (2017-2022)
4.2 Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Type (2023-2028)
5 Painful Diabetic Neuropathy Drug Breakdown Data by Application
5.1 Global Painful Diabetic Neuropathy Drug Historic Market Size by Application (2017-2022)
5.2 Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Painful Diabetic Neuropathy Drug Market Size (2017-2028)
6.2 North America Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022)
6.3 North America Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Painful Diabetic Neuropathy Drug Market Size (2017-2028)
7.2 Europe Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022)
7.3 Europe Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size (2017-2028)
8.2 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022)
8.3 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Painful Diabetic Neuropathy Drug Market Size (2017-2028)
9.2 Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022)
9.3 Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size (2017-2028)
10.2 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022)
10.3 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Daiichi Sankyo Company, Limited
11.1.1 Daiichi Sankyo Company, Limited Company Detail
11.1.2 Daiichi Sankyo Company, Limited Business Overview
11.1.3 Daiichi Sankyo Company, Limited Painful Diabetic Neuropathy Drug Introduction
11.1.4 Daiichi Sankyo Company, Limited Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.1.5 Daiichi Sankyo Company, Limited Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Detail
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Painful Diabetic Neuropathy Drug Introduction
11.2.4 Eli Lilly and Company Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.2.5 Eli Lilly and Company Recent Development
11.3 Johnson & Johnson Services, Inc
11.3.1 Johnson & Johnson Services, Inc Company Detail
11.3.2 Johnson & Johnson Services, Inc Business Overview
11.3.3 Johnson & Johnson Services, Inc Painful Diabetic Neuropathy Drug Introduction
11.3.4 Johnson & Johnson Services, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.3.5 Johnson & Johnson Services, Inc Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Painful Diabetic Neuropathy Drug Introduction
11.4.4 Novartis AG Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.4.5 Novartis AG Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Detail
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Painful Diabetic Neuropathy Drug Introduction
11.5.4 Pfizer Inc. Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.5.5 Pfizer Inc. Recent Development
11.6 Grunenthal GmbH
11.6.1 Grunenthal GmbH Company Detail
11.6.2 Grunenthal GmbH Business Overview
11.6.3 Grunenthal GmbH Painful Diabetic Neuropathy Drug Introduction
11.6.4 Grunenthal GmbH Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.6.5 Grunenthal GmbH Recent Development
11.7 ViroMed Co.
11.7.1 ViroMed Co. Company Detail
11.7.2 ViroMed Co. Business Overview
11.7.3 ViroMed Co. Painful Diabetic Neuropathy Drug Introduction
11.7.4 ViroMed Co. Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.7.5 ViroMed Co. Recent Development
11.8 Collegium Pharmaceutical, Inc
11.8.1 Collegium Pharmaceutical, Inc Company Detail
11.8.2 Collegium Pharmaceutical, Inc Business Overview
11.8.3 Collegium Pharmaceutical, Inc Painful Diabetic Neuropathy Drug Introduction
11.8.4 Collegium Pharmaceutical, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.8.5 Collegium Pharmaceutical, Inc Recent Development
11.9 Acorda Therapeutics, Inc
11.9.1 Acorda Therapeutics, Inc Company Detail
11.9.2 Acorda Therapeutics, Inc Business Overview
11.9.3 Acorda Therapeutics, Inc Painful Diabetic Neuropathy Drug Introduction
11.9.4 Acorda Therapeutics, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.9.5 Acorda Therapeutics, Inc Recent Development
11.10 Zydus Pharmaceuticals
11.10.1 Zydus Pharmaceuticals Company Detail
11.10.2 Zydus Pharmaceuticals Business Overview
11.10.3 Zydus Pharmaceuticals Painful Diabetic Neuropathy Drug Introduction
11.10.4 Zydus Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.10.5 Zydus Pharmaceuticals Recent Development
11.11 Mallinckrodt, Inc
11.11.1 Mallinckrodt, Inc Company Detail
11.11.2 Mallinckrodt, Inc Business Overview
11.11.3 Mallinckrodt, Inc Painful Diabetic Neuropathy Drug Introduction
11.11.4 Mallinckrodt, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.11.5 Mallinckrodt, Inc Recent Development
11.12 Macleods Pharmaceuticals Ltd.
11.12.1 Macleods Pharmaceuticals Ltd. Company Detail
11.12.2 Macleods Pharmaceuticals Ltd. Business Overview
11.12.3 Macleods Pharmaceuticals Ltd. Painful Diabetic Neuropathy Drug Introduction
11.12.4 Macleods Pharmaceuticals Ltd. Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.12.5 Macleods Pharmaceuticals Ltd. Recent Development
11.13 Lupin Pharmaceuticals
11.13.1 Lupin Pharmaceuticals Company Detail
11.13.2 Lupin Pharmaceuticals Business Overview
11.13.3 Lupin Pharmaceuticals Painful Diabetic Neuropathy Drug Introduction
11.13.4 Lupin Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.13.5 Lupin Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Painful Diabetic Neuropathy Drug Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Oral
Table 3. Key Players of Injection
Table 4. Key Players of Others
Table 5. Global Painful Diabetic Neuropathy Drug Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Painful Diabetic Neuropathy Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Painful Diabetic Neuropathy Drug Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Painful Diabetic Neuropathy Drug Market Share by Region (2017-2022)
Table 9. Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Painful Diabetic Neuropathy Drug Market Share by Region (2023-2028)
Table 11. Painful Diabetic Neuropathy Drug Market Trends
Table 12. Painful Diabetic Neuropathy Drug Market Drivers
Table 13. Painful Diabetic Neuropathy Drug Market Challenges
Table 14. Painful Diabetic Neuropathy Drug Market Restraints
Table 15. Global Painful Diabetic Neuropathy Drug Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Painful Diabetic Neuropathy Drug Market Share by Players (2017-2022)
Table 17. Global Top Painful Diabetic Neuropathy Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Painful Diabetic Neuropathy Drug as of 2021)
Table 18. Ranking of Global Top Painful Diabetic Neuropathy Drug Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Painful Diabetic Neuropathy Drug Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Painful Diabetic Neuropathy Drug Product Solution and Service
Table 22. Date of Enter into Painful Diabetic Neuropathy Drug Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Painful Diabetic Neuropathy Drug Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Type (2017-2022)
Table 26. Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Type (2023-2028)
Table 28. Global Painful Diabetic Neuropathy Drug Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Application (2017-2022)
Table 30. Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Painful Diabetic Neuropathy Drug Revenue Market Share by Application (2023-2028)
Table 32. North America Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022) & (US$ Million)
Table 33. North America Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028) & (US$ Million)
Table 34. Europe Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022) & (US$ Million)
Table 35. Europe Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028) & (US$ Million)
Table 36. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2017-2022) & (US$ Million)
Table 37. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2023-2028) & (US$ Million)
Table 38. Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022) & (US$ Million)
Table 39. Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028) & (US$ Million)
Table 40. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022) & (US$ Million)
Table 41. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028) & (US$ Million)
Table 42. Daiichi Sankyo Company, Limited Company Detail
Table 43. Daiichi Sankyo Company, Limited Business Overview
Table 44. Daiichi Sankyo Company, Limited Painful Diabetic Neuropathy Drug Product
Table 45. Daiichi Sankyo Company, Limited Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 46. Daiichi Sankyo Company, Limited Recent Development
Table 47. Eli Lilly and Company Company Detail
Table 48. Eli Lilly and Company Business Overview
Table 49. Eli Lilly and Company Painful Diabetic Neuropathy Drug Product
Table 50. Eli Lilly and Company Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 51. Eli Lilly and Company Recent Development
Table 52. Johnson & Johnson Services, Inc Company Detail
Table 53. Johnson & Johnson Services, Inc Business Overview
Table 54. Johnson & Johnson Services, Inc Painful Diabetic Neuropathy Drug Product
Table 55. Johnson & Johnson Services, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 56. Johnson & Johnson Services, Inc Recent Development
Table 57. Novartis AG Company Detail
Table 58. Novartis AG Business Overview
Table 59. Novartis AG Painful Diabetic Neuropathy Drug Product
Table 60. Novartis AG Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 61. Novartis AG Recent Development
Table 62. Pfizer Inc. Company Detail
Table 63. Pfizer Inc. Business Overview
Table 64. Pfizer Inc. Painful Diabetic Neuropathy Drug Product
Table 65. Pfizer Inc. Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 66. Pfizer Inc. Recent Development
Table 67. Grunenthal GmbH Company Detail
Table 68. Grunenthal GmbH Business Overview
Table 69. Grunenthal GmbH Painful Diabetic Neuropathy Drug Product
Table 70. Grunenthal GmbH Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 71. Grunenthal GmbH Recent Development
Table 72. ViroMed Co. Company Detail
Table 73. ViroMed Co. Business Overview
Table 74. ViroMed Co. Painful Diabetic Neuropathy Drug Product
Table 75. ViroMed Co. Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 76. ViroMed Co. Recent Development
Table 77. Collegium Pharmaceutical, Inc Company Detail
Table 78. Collegium Pharmaceutical, Inc Business Overview
Table 79. Collegium Pharmaceutical, Inc Painful Diabetic Neuropathy Drug Product
Table 80. Collegium Pharmaceutical, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 81. Collegium Pharmaceutical, Inc Recent Development
Table 82. Acorda Therapeutics, Inc Company Detail
Table 83. Acorda Therapeutics, Inc Business Overview
Table 84. Acorda Therapeutics, Inc Painful Diabetic Neuropathy Drug Product
Table 85. Acorda Therapeutics, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 86. Acorda Therapeutics, Inc Recent Development
Table 87. Zydus Pharmaceuticals Company Detail
Table 88. Zydus Pharmaceuticals Business Overview
Table 89. Zydus Pharmaceuticals Painful Diabetic Neuropathy Drug Product
Table 90. Zydus Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 91. Zydus Pharmaceuticals Recent Development
Table 92. Mallinckrodt, Inc Company Detail
Table 93. Mallinckrodt, Inc Business Overview
Table 94. Mallinckrodt, Inc Painful Diabetic Neuropathy DrugProduct
Table 95. Mallinckrodt, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 96. Mallinckrodt, Inc Recent Development
Table 97. Macleods Pharmaceuticals Ltd. Company Detail
Table 98. Macleods Pharmaceuticals Ltd. Business Overview
Table 99. Macleods Pharmaceuticals Ltd. Painful Diabetic Neuropathy DrugProduct
Table 100. Macleods Pharmaceuticals Ltd. Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 101. Macleods Pharmaceuticals Ltd. Recent Development
Table 102. Lupin Pharmaceuticals Company Detail
Table 103. Lupin Pharmaceuticals Business Overview
Table 104. Lupin Pharmaceuticals Painful Diabetic Neuropathy DrugProduct
Table 105. Lupin Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022) & (US$ Million)
Table 106. Lupin Pharmaceuticals Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Painful Diabetic Neuropathy Drug Market Share by Type: 2021 VS 2028
Figure 2. Oral Features
Figure 3. Injection Features
Figure 4. Others Features
Figure 5. Global Painful Diabetic Neuropathy Drug Market Share by Application in 2021 & 2028
Figure 6. Hospital Case Studies
Figure 7. Clinic Case Studies
Figure 8. Others Case Studies
Figure 9. Painful Diabetic Neuropathy Drug Report Years Considered
Figure 10. Global Painful Diabetic Neuropathy Drug Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Painful Diabetic Neuropathy Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Painful Diabetic Neuropathy Drug Market Share by Region: 2021 VS 2028
Figure 13. Global Painful Diabetic Neuropathy Drug Market Share by Players in 2021
Figure 14. Global Top Painful Diabetic Neuropathy Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Painful Diabetic Neuropathy Drug as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Painful Diabetic Neuropathy Drug Revenue in 2021
Figure 16. North America Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 17. North America Painful Diabetic Neuropathy Drug Market Share by Country (2017-2028)
Figure 18. United States Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Painful Diabetic Neuropathy Drug Market Share by Country (2017-2028)
Figure 22. Germany Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. France Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. U.K. Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Italy Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Russia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Nordic Countries Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Asia-Pacific Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Asia-Pacific Painful Diabetic Neuropathy Drug Market Share by Region (2017-2028)
Figure 30. China Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Japan Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. South Korea Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Southeast Asia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. India Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Australia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Latin America Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Latin America Painful Diabetic Neuropathy Drug Market Share by Country (2017-2028)
Figure 38. Mexico Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Brazil Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Middle East & Africa Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Middle East & Africa Painful Diabetic Neuropathy Drug Market Share by Country (2017-2028)
Figure 42. Turkey Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Saudi Arabia Painful Diabetic Neuropathy Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Daiichi Sankyo Company, Limited Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 45. Eli Lilly and Company Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 46. Johnson & Johnson Services, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 47. Novartis AG Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 48. Pfizer Inc. Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 49. Grunenthal GmbH Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 50. ViroMed Co. Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 51. Collegium Pharmaceutical, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 52. Acorda Therapeutics, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 53. Zydus Pharmaceuticals Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 54. Mallinckrodt, Inc Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 55. Macleods Pharmaceuticals Ltd. Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 56. Lupin Pharmaceuticals Revenue Growth Rate in Painful Diabetic Neuropathy Drug Business (2017-2022)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
